Pharmaceutical Solid Dosage Contract Manufacturing Market May Set New Growth Story | BioPharma Solutions, Pillar5 Pharma, Emergent BioSolutions, Haupt Pharma
iCrowd Newswire
12 May 2021, 21:05 GMT+10
The latest analysis released by HTF MI on COVID-19 Outbreak-Global Pharmaceutical Solid Dosage Contract Manufacturing Market Outlook 2021 Survey results sheds light on how investment and competitive landscape is impacted due to significant changes in the COVID-19 Outbreak- Pharmaceutical Solid Dosage Contract Manufacturing Industry. The research coverage includes analysis on companies such as Covance, Althea Technologies, Fresenius Kabi, Mikart, Emergent BioSolutions, Catalent Pharma Solutions, BioPharma Solutions, Abbott Laboratories, Associates of Cape Cod, Pillar5 Pharma, Haupt Pharma, Lyophilization Technology, DPT Laboratories, Cytovance Biologics, Halo Pharmaceutical, Alkermes & Jubilant Life Sciences Limited etc. It is expected that the healthcare and life sciences industry
April 27, 2021 at 5:00 pm
Shimano Linkglide is a new spec option for the brand’s XT and Deoremountain bike groupsets that uses a new tooth profile to reduce wear.
Advertisement
Designed for both e-MTBs and conventional mountain bike drivetrains, it’s aimed at reducing tooth wear under high torque use, without impacting shift quality, leading to lower maintenance and replacement costs, according to Shimano.
Linkglide will be an option initially on 1×11-speed Deore XT and 1×10-speed Deore drivetrains, and Shimano says that it ups durability three-fold over its Hyperglide cassettes in muddy conditions.
This, it says, results in fewer chain skips and smoother shifting, as well as increased drivetrain longevity.
Canntab Granted 2nd Patent For Immediate Release Cannabidiol Formulation Tablets
News provided by
Share this article
Company or
Canntab ), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is thrilled to announce the Canadian Intellectual Property Office (
CIPO ) has allowed Canadian Patent No. CA 3050150 to Canntab, related to its proprietary cannabidiol formulations with a priority date of January 23, 2017. The term of the patent expires on January 22, 2038.
Canntab s Legal Counsel on intellectual property, Gavin Bogle of Magyar, Bogle & O Hara LLP said, The allowance of Canntab s patent by the Canadian Intellectual Property Office provides fundamental intellectual protection for Canntab s innovative tableting technology and validates the years of research and development the company has conducted. The Company now has patent protection in Canada and the USA providing an international scope to the Company s expanding